Trials in High Point, North Carolina
Here are the top 10 medical studies for alzheimer's disease in High Point, North Carolina
Popular Filters
Phase 3 Trials
Glucagon-like peptide-1 (GLP-1) receptor agonist
Semaglutide for Early Alzheimer's Disease
Recruiting1 awardPhase 3
Matthews, North Carolina
This trial is to test whether the medication semaglutide has a positive effect on early Alzheimer's disease. The study will last for up to 173 weeks, and participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans, and at 10 of the clinic visits participants will have blood samples taken. The trial is only for women.
Glucagon-like peptide-1 (GLP-1) receptor agonist
Semaglutide for Early Alzheimer's Disease
Recruiting1 awardPhase 3
Matthews, North Carolina
This trial is testing whether semaglutide has a positive effect on early Alzheimer's disease by comparing it to a placebo. There will be 17 clinic visits and 1 phone call with the study doctor, and various tests and scans will be performed. The study will last for up to 173 weeks.
Monoclonal Antibodies
Lecanemab for Alzheimer's Disease
Recruiting1 awardPhase 3
Winston-Salem, North Carolina
This trial is testing lecanemab, a drug aimed at improving memory and thinking skills in people with early signs of Alzheimer's disease. The drug works by reducing amyloid plaques in the brain, which are believed to contribute to Alzheimer's. Researchers want to see if lecanemab is effective over several years.
Monoclonal Antibodies
Donanemab for Early Alzheimer's Disease
Recruiting1 awardPhase 3
Washington, District of Columbia
This trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.
Trials With No Placebo
Behavioral Intervention
Physical Activity for Alzheimer's Disease
Recruiting1 award5 criteria
Greensboro, North Carolina
This trial will assess the effects of exercise on middle-aged adults who have a heightened risk of Alzheimer's disease due to family history. The investigators will also assess the extent to which this effect is moderated by apolipoprotein epsilon-4 (APOE4) carrier status.
Behavioral Intervention
Palliative Care Program for Alzheimer's Disease
Recruiting1 award2 criteria
Chapel Hill, North Carolina
This trial will study if a program of dementia-specific palliative care, standardized caregiver education, and transitional care can reduce burdensome hospital transfers, improve symptom treatment and control, augment supportive services, and reduce nursing home transitions for patients, and improve caregiver outcomes of communication, shared decision-making and distress.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.